Everest Medicines (HKG:1952) said it agreed to acquire a license to Corxel Pharmaceuticals' eye drop LNZ100 for the greater China region, according to a Monday filing with the Hong Kong bourse.
The firm said it would make an upfront payment for the license, as well as milestone payouts and royalties on the sales of the presbyopia treatment.
The drug is already approved in the U.S. and is expected to receive Chinese regulatory nod in the first quarter of 2027.